

Psoriasis and Cardiovascular Comorbidities

Abdelkader Jalil El Hangouche^{1,2,3*}, Hanatou Seydou Sadou Maiga², Nawal Doghmi², Latifa Oukerraj², Hanan Rkain¹, Taoufiq Dakka¹, Mohammed Cherti²

¹Exercise Physiology and Autonomic Nervous System Team "EPE-SNA", Faculty of Medicine and Pharmacy of Rabat, Mohamed V University, Rabat, Morocco

²Department of Cardiology B, Ibn Sina Hospital, Mohamed V University, Rabat, Morocco

³Laboratory of Physiology, Faculty of Medicine and Pharmacy of Tangier, Abdelmalek, Essaadi University, Tangier, Morocco

Review Article

*Corresponding author

Abdelkader Jalil El
Hangouche

Article History

Received: 16.12.2017

Accepted: 25.12.2017

Published: 30.12.2017

DOI:

10.36347/sjams.2017.v05i12.074



Abstract: Psoriasis is one of the most prevalent T-cell-mediated chronic inflammatory disorders affecting the skin, scalp, nails, and joints. Its pathophysiology is characterized by immune responses mediated by type 1 and type 17 helper T lymphocytes and synthesis of various cytokines that produce inflammation of the skin and joints. In recent years, several studies demonstrated that psoriasis is associated with an increased risk of various cardiovascular diseases. This report synthesizes the current understanding of the prevalence and characteristics of cardiovascular comorbidities in patients with psoriatic disease, and the importance of screening for and treating modifiable cardiometabolic risk factors.

Keywords: cardiovascular disease; atherosclerosis; inflammatory disorders; T-cell-mediated; metabolic syndrome.

INTRODUCTION

Psoriasis is a recalcitrant disease of chronic and systemic inflammation affecting approximately 2- 3% of the world population [1-2]. The most common type is psoriasis vulgaris, which is characterized by the presence of papulosquamous plaques in the skin. Psoriasis can occur at any age, but the onset is generally between the ages of 18 and 35 years. The plaque severity and degree of affected body surface area vary throughout an individual's life. Regardless of disease severity, psoriasis is associated with significant morbidity that extends beyond the skin [3]. Indeed, in recent years, several studies demonstrated that psoriasis is associated with an increased risk of various cardiovascular diseases, including peripheral arterial disease [4], coronary artery disease, [5] atrial fibrillation, ischemic stroke, [6] deep venous thromboses, pulmonary emboli, [7] and renal insufficiency [8].

To date, the exact underlying pathways that link cardiometabolic comorbidities to psoriasis are complex and not fully understood [9]; Nevertheless, several recent observational studies provide evidence that common inflammatory pathways are likely involved in the pathophysiology of psoriasis and cardiovascular inflammation, both of which are associated with a chronic proinflammatory, proangiogenic, and prothrombotic state [10-11].

However, it is still unclear whether psoriatic inflammation primarily contributes to the development of cardiometabolic comorbidities, or whether preexisting metabolic dysfunction causes immunologic dysregulation that then leads to the development of psoriasis [12].

This report synthesizes the current understanding of the prevalence and characteristics of cardiovascular comorbidities in patients with psoriatic disease, and the importance of screening for and treating modifiable cardiometabolic risk factors.

Psoriasis and metabolic syndrome

The metabolic syndrome refers to the commonly occurring disorder comprising central obesity, atherogenic dyslipidemia, hypertension, and insulin resistance [13]. The definition of metabolic syndrome requires central obesity (BMI > 30 kg/m²) and any two of the following abnormalities: elevated plasma triglycerides, reduced HDL cholesterol, elevated blood pressure and raised fasting plasma glucose [14-15]. It is associated with accelerated atherosclerosis in response to chronic inflammation and vascular

endothelial dysfunction and has long been associated with psoriatic disease [4-18].

In a study comparing 625 hospitalized psoriasis patients and 1044 non psoriasis patients, hyperlipidemia, hypertension, coronary artery disease, type 2 diabetes, and increased Body mass index are increased in psoriasis than in controls [14-19].

Langan *et al.* performed a cross-sectional study of patients with psoriasis in the United Kingdom for whom information on body surface area involvement by psoriasis was available and found a positive dose dependent relationship between objective measures of psoriasis severity and metabolic syndrome [20].

Obesity

Recent studies have shown that obesity may precede the onset of psoriasis as a risk factor [21-22]. In meta-analysis of 16 observational studies, the pooled odds ratio (OR) for obesity among patients with psoriasis was 1.66 (95% confidence interval (CI) 1.46–1.89) compared with those without psoriasis. Among studies that accounted for psoriasis severity, the pooled OR for the association between obesity and mild and severe psoriasis were 1.46 (95% CI, 1.17-1.82) and 2.23 (95% CI, 1.63- 3.05), respectively [23] and one incidence study found that psoriasis patients have a hazard ratio of 1.18 (95% CI 1.14–1.23) for new-onset obesity [24].

Hypertension

Several studies have reported an increase in the prevalence of hypertension in psoriasis patients [21]. The majority of these authors establish a relationship between the severity of psoriasis and the risk of hypertension [25-26].

In a meta-analysis of 24 observational studies, patients with psoriasis had significantly increased odds of hypertension (OR, 1.58; 95% CI, 1.42–1.76), and the prevalence was greatest in those with severe psoriasis and psoriatic arthritis [27].

Two cohort studies also observed psoriasis to be associated with an increased risk of incident hypertension [28-29]. In addition, studies of patients with hypertension suggest more severe hypertension and poorly controlled blood pressure among patients with psoriasis compared with those without psoriasis [23-30-31]. Whereas other studies have not observed a significant association between psoriasis and hypertension [21-32].

Diabetes mellitus

Several recent observational studies provide evidence that the risk of diabetes is higher in patients with psoriasis compared with a healthy control group [21].

A meta-analysis of 5 cohort studies assessing the risk of incident diabetes among patients with psoriasis found a pooled relative risk (RR) for diabetes of 1.27 (95% CI, 1.16-1.40) [33]. This risk increases with the duration and severity of psoriasis and it is not related to a high body mass index alone [21].

Moreover, diabetic patients with psoriasis appear to be more likely to require pharmacologic management [34] and suffer from macro- and microvascular diabetes complications than diabetic patients without psoriasis [23-35].

Dyslipidemia

Dyslipidemia may be more prevalent among patients with than without psoriasis [23]. In a systematic review, 20 of 25 included studies demonstrated a significant correlation between psoriasis and lipid profile abnormalities including elevated triglyceride levels in 16%, high-density lipoprotein cholesterol level of less than 40 mg/dL in 12%, and unspecified hyperlipoproteinemia in 8%. However in 5 of included studies, there were no differences in lipid levels between psoriasis patients and controls [4-36].

The directionality of the association between psoriasis and dyslipidemia remains unclear; some studies suggest dyslipidemia may be a risk factor for developing psoriasis [37-38].

Psoriasis and coronary artery disease

Patients with psoriatic disease are at an increased risk of coronary artery disease [5,39,40] and myocardial infarction [4,41-43]. In a prospective, population based cohort study, 130,976 patients with psoriasis was compared to 556,995 controls for myocardial infarction with a mean follow-up of 5.4 years ; The myocardial infarction incidence per 1000 person-years for control patients and patients with mild and severe psoriasis was 3.58 (95% CI, 3.52-3.65), 4.04 (95% CI, 3.88-4.21), and 5.13 (95% CI, 4.22-6.17), respectively [44].

In studies that stratified patients by age, the risk seemed to be greatest in younger patients [5]. Furthermore, data from the US Nurses' Health Study II demonstrated that women with psoriatic arthritis were significantly more likely to have a nonfatal myocardial infarction than women with psoriasis alone [43], suggesting that joint involvement may also confer greater risk [4].

Atrial fibrillation

Atrial fibrillation is also more prevalent in patients with psoriasis [6,45]. A cohort study analyze the risk of Atrial fibrillation in the patients with psoriasis; the authors showed that in the patients with mild psoriasis, the adjusted risk ratios for Atrial fibrillation were 1.50 (95% CI: 1.21–1.86) in those under 50 and 1.16 (1.08–1.24) in the patients over 50

years, respectively. And in the patients with severe psoriasis, a higher risk of Atrial fibrillation was observed with RR = 2.98 (95% CI: 1.80–4.92) in those under 50 and 1.29 (95% CI: 1.01–1.65) in the patients over 50 years, suggesting that psoriasis was associated with an increased risk of Atrial fibrillation independent of age, gender and co-morbidity [6,46].

In addition, in a cohort study of patients with nonvalvular atrial fibrillation who had not been treated with anticoagulation, those with psoriasis had significantly higher rates of thromboembolism and related mortality, which exceeded that predicted by their CHA2DSVASc score by 2.6 to 3.4 times [45].

Impact of therapies on psoriasis and cardiovascular disease

Since inflammation is the driving link between psoriasis and cardiovascular disease, it is reasonable that targeting inflammation would improve cardiovascular outcomes. Unfortunately, traditional anti-inflammatory agents [47, 48], as well as the systemic immunomodulatory [49-50], have been associated with an increased risk of dyslipidemia, homocysteinemia, hypertension, and adverse cardiovascular events [4]. Despite the effects of these medications, available data suggest that some systemic agents can be cardio protective [3]. Low-dose methotrexate has been shown to reduce the risk of major cardiovascular disease events in psoriasis patient [51]. Moreover multiple studies have shown that tumor necrosis factor-blocking agents seem to be cardio protective [52-53]. In addition supplementation with folic acid, vitamin B6, and B12, had significantly reduced vascular disease compared with untreated patients with psoriasis (relative risk, 0.73; 95% CI, 0.55-0.98) [51].

Recently, a meta-analysis of 6 studies in patients with psoriasis or psoriatic arthritis revealed a significant protective effect of all systemic medications on relative risk of cardiovascular disease [47]. Furthermore, cardiovascular medications may affect psoriasis. Statins have been suggested as a potential treatment for psoriasis because of their anti-inflammatory properties [3]. A pilot study evaluated the effectiveness of simvastatin in patients with severe psoriasis found that statins can correct lipid metabolism and reduce cutaneous lesions in psoriasis [54]. More recently, some authors reported a decreased risk of psoriasis associated with statin intake [14, 55]. Also oral statins may enhance the therapeutic effect of topical steroids against psoriasis [56]. Beta-blockers have been suggested to induce and exacerbate psoriasis [57,58]. However, in many cases, betablockers were associated with a psoriasiform reaction rather than psoriasis, and histologic testing, did not support the diagnosis of psoriasis [3]. More recently, A large population-based case-control analysis does not support that betablocker use is associated with an increased risk of psoriasis [59]. In addition, other antihypertensives

have been suspected to have an association with psoriasis [60]. Angiotensin-converting enzyme inhibitors [60-62], calcium channel blockers [63], and clonidine [64] have been reported to have a possible association with psoriasis [3]. However, the results of the studies have remained controversial [9,65,66].

CONCLUSION

There is growing argument supporting an association between psoriasis and cardiovascular comorbidities. Until more evidence is available, and multidisciplinary guidelines, all patients with moderate to severe psoriasis should be considered to be at a higher risk of cardiovascular disease and managed accordingly.

REFERENCES

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. *Arch Dermatol.* 2005 Dec;141(12):1537–41.
2. Foundation, N.P. National Psoriasis Foundation. [cited 2009 July 10]; Psoriasis Statistics]. Available from: <http://www.psoriasis.org/about/stats>.
3. Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors. *The American Journal of Medicine.* 2014 Jan 1;127(1):12–8.
4. Shahwan KT, Kimball AB. Psoriasis and Cardiovascular Disease. *Medical Clinics.* 2015 Nov 1;99(6):1227–42.
5. Horreau C, Pouplard C, Brenaut E, Barnette T, Misery L, Cribier B. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. *J Eur Acad Dermatol Venereol.* 2013 Aug;27 Suppl 3:12–29.
6. Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlott M, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. *European heart journal.* 2011 Aug 12;33(16):2054–64.
7. Ahlehoff O, Gislason GH, Lindhardsen J, Charlott MG, Jørgensen CH, Olesen JB, et al. Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study. *PLOS ONE.* 2011 Mar 25;6(3):e18125.
8. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *BMJ.* 2013 Oct 15;347:f5961.
9. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. *Clin Dermatol.* 2018 Feb;36(1):21–8.
10. Ryan C, Menter A. Psoriasis and cardiovascular disorders. *G Ital Dermatol Venereol.* 2012 Apr;147(2):179–87.
11. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative

- stress: common mechanisms linking psoriasis with atherosclerosis. *J Dermatol Sci*. 2011 Jul;63(1):1–9.
12. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. *Dermatol Clin*. 2015 Jan;33(1):41–55.
 13. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. *Clinics in Dermatology*. 2018 Jan 1;36(1):14–20.
 14. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. *Clin Dermatol*. 2014 Jun;32(3):343–50.
 15. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. *J Atheroscler Thromb*. 2005;12(6):295–300.
 16. Baeta IGR, Bittencourt FV, Gontijo B, Goulart EMA. Comorbidities and cardiovascular risk factors in patients with psoriasis. *An Bras Dermatol*. 2014 Oct;89(5):735–44.
 17. Karoli R, Fatima J, Shukla V, Dhillon KS, Khanduri S, Maini S, Chandra A. A study of cardio-metabolic risk profile in patients with psoriasis. *J Assoc Physicians India*. 2013 Nov;61(11):798–803.
 18. Mok CC, Ko GTC, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. *Arthritis Care Res (Hoboken)*. 2011 Feb;63(2):195–202.
 19. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Arch Dermatol Res*. 2006 Dec;298(7):321–8.
 20. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. *Journal of Investigative Dermatology*. 2012 Mar 31;132(3):556–62.
 21. Frers RK, Bissoendial RJ, Montoya SF, Kerzberg E, Castilla R, Tak PP, Milei J, Capani F. Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. *IJC Metabolic & Endocrine*. 2015 Mar 31;6:43–54.
 22. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. *Arch Intern Med*. 2007 Aug 13;167(15):1670–5.
 23. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. *Journal of the American Academy of Dermatology*. 2017 Mar 31;76(3):377–90.
 24. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes*. 2012 Dec;2(12):e54.
 25. Cohen AD, Weitzman D, Dreiherr J. Psoriasis and hypertension: a case-control study. *Acta Derm Venereol*. 2010;90(1):23–6.
 26. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. *J Drugs Dermatol*. 2008 Apr;7(4):373–7.
 27. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. *J Hypertens*. 2013 Mar;31(3):433–442; discussion 442–443.
 28. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. *Arch Dermatol*. 2009 Apr;145(4):379–82.
 29. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. *Br J Dermatol*. 2008 Sep;159(4):895–902.
 30. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. *PLoS ONE*. 2011 Mar 29;6(3):e18227.
 31. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, Troxel AB, Gelfand JM. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. *JAMA dermatology*. 2015 Feb 1;151(2):161–9.
 32. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, Jones PB, Cornish J, McQueen FM. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. *Arthritis research & therapy*. 2010 Aug 26;12(4):R164.
 33. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. *JAMA Dermatol*. 2013 Jan;149(1):84–91.
 34. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. *Arch Dermatol*. 2012 Sep;148(9):995–1000.
 35. Armstrong AW, Guérin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. *J Am Acad Dermatol*. 2015 Jun;72(6):968–977.e2.
 36. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. *Br J Dermatol*. 2013 Mar;168(3):486–95.
 37. Wu S, Li W-Q, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. *Arthritis & Rheumatology (Hoboken, NJ)*. 2014 Feb;66(2):304–10.

38. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. *J Am Acad Dermatol*. 2006 Apr;54(4):614–21.
39. Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. *Am J Cardiol*. 2012 Apr 1;109(7):976–80.
40. Picard D, Bénichou J, Sin C, Abasq C, Houivet E, Koning R, Cribier A, Veber B, Dujardin F, Eltchaninoff H, Joly P. Increased prevalence of psoriasis in patients with coronary artery disease: results from a case–control study. *British Journal of Dermatology*. 2014 Sep 1;171(3):580-7.
41. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. *J Am Heart Assoc*. 2013 Apr 4;2(2):e000062.
42. Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study. *J Cutan Med Surg*. 2013 Dec;17(6):398–403.
43. Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, Qureshi AA. Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study. *British Journal of Dermatology*. 2012 Apr 1;166(4):811-8.
44. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006 Oct 11;296(14):1735–41.
45. Ahlehoff O, Gislason G, Lamberts M, Folke F, Lindhardsen J, Larsen CT, Torp-Pedersen C, Hansen PR. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. *Journal of internal medicine*. 2015 Apr 1;277(4):447-55.
46. Zhang Z, Li G, Liu T. Psoriasis and risk of atrial fibrillation. *International Journal of Cardiology*. 2015 Apr 15;185:301–3.
47. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Annals of the rheumatic diseases*. 2015 Mar 1;74(3):480-9.
48. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. *The American journal of cardiology*. 2007 Jan 1;99(1):91-8.
49. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease. *Int J Med Sci*. 2010 Aug 19;7(5):284–9.
50. Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? *Eur Heart J*. 2012 Aug;33(16):1989–91.
51. Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. *Journal of the American Academy of Dermatology*. 2005 Feb 28;52(2):262-7.
52. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis & Rheumatology*. 2007 Sep 1;56(9):2905-12.
53. Jacobsson LT, Turesson C, Nilsson JÅ, Petersson IF, Lindqvist E, Saxne T, Geborek P. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2007 May 1;66(5):670-5.
54. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. *Journal of the American Academy of Dermatology*. 2007 Sep 1;57(3):529-31.
55. Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. *Dermatology*. 2009;218(2):103-9.
56. Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. *Nigerian journal of medicine: journal of the National Association of Resident Doctors of Nigeria*. 2010;19(1):58-61.
57. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol*. 1986 Nov;15(5 Pt 1):1007–22.
58. Neumann HA, Van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor-blocking agents. *Dermatology*. 1981;162(5):330-5.
59. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case–control study. *British journal of dermatology*. 2008 Jun 1;158(6):1299-307.
60. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. *Clin Dermatol*. 1998 Jun;16(3):333–51.
61. Cohen AD, Bonnefeyt DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. *Acta Derm Venereol*. 2005;85(4):299–303.

62. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. *Br J Dermatol.* 2002 Sep;147(3):617–8.
63. Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. *Acta Derm Venereol.* 2001 Nov;81(5):347–9.
64. Wilkin J. Exacerbation of Psoriasis During Clonidine Therapy. *Arch Dermatol.* 1981 Jan 1;117(1):4–4.
65. Wu S, Han J, Li W-Q, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. *JAMA Dermatol.* 2014 Sep;150(9):957–63.
66. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. *Int J Dermatol.* 2010 Dec;49(12):1351–61.